As of November 6, 2026, Orthofix Medical Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 9, 2026 to June 11, 2026 (Form 8-K, June 11, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Orthofix Medical Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Orthofix Medical Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-09 to 2026-06-11. Every row below is cited to the filing it comes from, and this page adds each new change as Orthofix Medical Inc. files it.
Also on the record for Orthofix Medical Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 8.01% of the class | 5%+ stakes | Source |
| May 27, 2026 | Stake report, Schedule 13D/A, by Juniper Investment Company, LLC | 11% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 6.73% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 6.69% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13D/A, by Juniper Investment Company, LLC | 9.6% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 5.65% of the class | 5%+ stakes | Source |
| October 21, 2025 | Stake report, Schedule 13D/A, by Juniper Investment Company, LLC | 8.2% of the class | 5%+ stakes | Source |
| September 25, 2025 | Stake report, Schedule 13D/A, by Juniper Investment Company, LLC | 7.2% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 7.54% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Orthofix Medical Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Orthofix Medical Inc. and the records around it.
Orthofix Medical Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Juniper Targeted Opportunity Fund, L.P. also filed stake reports on 3 other companies: Allient Inc. (Aug 2026), Lincoln Educational Services Corporation (Jun 2026), Artivion, Inc. (Aug 2025)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Orthofix Medical Inc.
Get an email when Orthofix Medical Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Orthofix Medical Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Orthofix Medical Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Orthofix Medical Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-11 | Reported | not named in the filing | 8-K, 2026-06-11 | ||
| 2026-04-09 | Reported | not named in the filing | 8-K, 2026-04-09 |
New leaders reset buying decisions — get the Full Report on Orthofix Medical Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Orthofix Medical Inc., with the record behind each one.
Find candidates like senior executive at Orthofix Medical Inc.Every change, in the filing's words
Reported
The Company's named executive officers are participants in the SPP.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
- Approval of Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan On June 10, 2026, Orthofix Medical Inc. (the "Company") held its 2026 Annual Meeting of Shareholders (the "Annual Meeting").
- At the Annual Meeting, the Company's shareholders approved Amendment No. 5 (the "SPP Amendment") to the Company's Second Amended and Restated Stock Purchase Plan (as previously amended, the "SPP").
- The SPP Amendment increases the number of shares of the Company's common stock available for issuance under the SPP by 1,250,000 shares.
- The SPP Amendment does not provide for any other changes to the SPP.
- The text of the SPP and the SPP Amendment are also set forth as Appendix A to the Company's proxy statement for the Annual Meeting, and the terms of the SPP and the SPP Amendment are further described in pages 73-75 of such proxy statement for the Annual Meeting.
Reported
Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers.
- On April 9, 2026, the Company announced that Max Reinhardt, the Company's President, Global Spine, will be departing as an executive and employee on or about June 12, 2026.
- The Company expects that Mr. Reinhardt's departure will be treated under his change in control and severance agreement with the Company as either a termination of employment without Cause, or resignation for Good Reason, during a Non-CIC Period, and that he will be entitled to receive the payments and benefits provided for thereunder, subject to compliance with the terms and conditions of such agreement.
Tools for this story
Each opens in a new tab, filled in for Orthofix Medical Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.